ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > lab req form

<< Previous

Bullboard Posts

Next >>

Comment by Mole101on May 10, 2021 7:04pm

156 Views

Post# 33170582

RE:RE:RE:RE:lab req form

Covid-19 test falls outside of the Neuroimmunology bread and butter tests that BCNI it's known for.

We know they got their BC DIAGNOSTIC ACCREDITATION PROGRAM first instead of going for HC approval . I'm wandering if they are looking to get that now , after getting all the validations necessary over the last few months by doing work with the Covid task force and https://www.bccdc.ca/health-professionals/clinical-resources/covid-19-care/covid-19-serology-care-covid-study..If you're licensing the test shouldn't you need that approval ? .. j